Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Soins ; 64(841): 38-39, 2019 Dec.
Artigo em Francês | MEDLINE | ID: mdl-31864511

RESUMO

In 2016, the fondation Santé Service made an evaluation of patients' satisfaction when the trastuzumab was injected subcutaneously. Made first at the hospital then at home, this injection way reduce the treatment duration at five minutes. The majority of patients will recommended this way of administration.


Assuntos
Serviços de Assistência Domiciliar , Satisfação do Paciente , Trastuzumab/administração & dosagem , Humanos , Injeções Subcutâneas
3.
Bull Cancer ; 105(12): 1126-1134, 2018 Dec.
Artigo em Francês | MEDLINE | ID: mdl-30466957

RESUMO

In 2013, the European Medicines Agency authorized a new pharmaceutical formulation of the trastuzumab for breast cancer treatment. The latter allows a sub-cutaneous injection that reduces significantly the injection time and permits an administration at home. This study aims to assess the experience of patients treated by trastuzumab subcutaneously at home in 2016, and the experience of the nurses who performed these injections. In 2017, a retrospective survey by phone calls could gather the impressions from 84 patients on their treatment. And 60 nurses answered to a written survey. The whole treatment session is estimated to last 30minutes to one hour by most of the patients (60%) and the nurses (85%), with an injection duration below 5 minutes (according to 71% of patients and 77% of nurses). The main side effects described were: rash (reported by 40% of patients and 52% of nurses) and pain (32% of patients and 68% of nurses). Among patients feeling pain, it was estimated as brief and weak by two thirds of them. Eighty-six per cent of patients found the session pleasant. The general impression of the nurses was also satisfying for almost all of them (89%). Overall, the feedback about subcutaneous injections of trastuzumab at home is very positive, for patients as for nurses. This new formulation improves quality and comfort in patients' care.


Assuntos
Antineoplásicos Imunológicos/administração & dosagem , Neoplasias da Mama/tratamento farmacológico , Serviços de Assistência Domiciliar , Trastuzumab/administração & dosagem , Administração Cutânea , Adulto , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos Imunológicos/efeitos adversos , Feminino , Humanos , Pessoa de Meia-Idade , Recursos Humanos de Enfermagem , Dor Processual/etiologia , Satisfação do Paciente , Estudos Retrospectivos , Fatores de Tempo , Trastuzumab/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...